

Aktuell rekrutierende Studien am Hirntumorzentrum des USZ

Titel	Phase	Studienleitung	Erkrankung und wichtigste Einschlusskriterien	Ansprechpartner
AGILE An international, seamless phase II/III response adaptive randomization platform trial designed to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma	II/III	GCAR	Glioblastom - Neudiagnose - 1. Rezidiv (genaue Verfügbarkeit der Kohorten im Einzelfall zu klären)	Prof. Dr. M. Weller michael.weller@usz.ch
CAAA601A52101 A dose finding study of [177Lu]Lu-DOTA-TATE in newly diagnosed glioblastoma in combination with standard of care and in recurrent glioblastoma as a single agent	I	Novartis	Glioblastom - Neudiagnose - 1. oder 2. Rezidiv (genaue Verfügbarkeit der Kohorten im Einzelfall zu klären)	Prof. Dr. M. Weller michael.weller@usz.ch
Debio 0123 -105 Phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma	I/II	Debiopharm	Rezidiv - Glioblastom - Astrozytom, IDH mut, WHO-Grad 3 (weitere Kohorten für Patienten mit Neudiagnose Glioblastom im Verlauf)	Prof. Dr. P. Roth patrick.roth@usz.ch
EDO-S101-1006 Study of tinostamustine for adjuvant treatment of glioblastoma	I	Mundipharma	Neudiagnose Glioblastom - MGMT-Promotor unmethyliert - Mindestens Teilresektion	Prof. Dr. P. Roth patrick.roth@usz.ch
CNS-201 A study of berubicin in adult subjects with recurrent glioblastoma multiforme	II	CNS Pharmaceuticals	Rezidiv Glioblastom	Prof. Dr. M. Weller michael.weller@usz.ch
EF-32 (TRIDENT) A randomized open-label study of OPTUNE® (TTFIELDS, 200KHZ) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma	III	Novocure	Neudiagnose Glioblastom	Prof. Dr. P. Roth patrick.roth@usz.ch
Gliostar A study to evaluate safety and efficacy of L19TNF plus lomustine in patients With glioblastoma at first progression	I/II	Philogen	1. Rezidiv Glioblastom	Dr. T. Weiss tobias.weiss@usz.ch

Gliosun A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma	I/II	Philogen	Neudiagnose Glioblastom	Dr. T. Weiss tobias.weiss@usz.ch
GLUOGLIO A phase Ib/II randomized, open label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma	I/II	UZH, H.G. Wirsching	Neudiagnose Glioblastoma	PD Dr. H.G. Wirsching hans-georg.wirsching@usz.ch
IT-IO Intrathecal double checkpoint inhibition	I	UZH	Leptomeningeale Metastasierung bei NSCLC oder Melanom	Dr. E. Le Rhun emilie.lerhun@usz.ch
ON-TRK Study to learn more about the safety and effectiveness of the drug VITRAKVI during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started	IV	Bayer	NTRK fusion-positiver Tumor (Indikation für Behandlung mit NTRK-Inhibitor)	Prof. Dr. M. Weller michael.weller@usz.ch
ONC201-108 ONC201 in H3 K27M-mutant diffuse glioma following radiotherapy	III	Chimerix	Gliom mit H3 K27M-Mutation	Dr. E. Le Rhun emilie.lerhun@usz.ch
PARPA-293-002 Phase I/II study of NMS-03305293+TMZ in adult patients with recurrent glioblastoma	I	Nerviano	Diffuses Gliom (Astrozytom/Oligodendrogliom/Glioblastom), erstes Rezidiv nach Chemotherapie oder Radiochemotherapie	PD Dr. D. Gramatzki dorothee.gramatzki@usz.ch
ReSurge Randomisierte Phase II-Studie zum Stellenwert der Resektion von Glioblastomen-Rezidiven	II	A. Raabe, Bern	1. Rezidiv eines Glioblastoms mit resezierbarem KM-aufnehmendem Tumoranteil	Prof. Dr. L. Regli luca.regli@usz.ch
STRIKE Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or NSCLC	III	ETOP	Neu diagnostizierte bzw. unbehandelte asymptomatische oder oligosymptomatische Hirnmetastasen eines Melanoms oder NSCLC	Prof. Dr. M. Weller michael.weller@usz.ch
Glodrive		USZ, KSL S. Hofer	Glioblastom – Beurteilung der Fahreignung	Dr. S. Hofer silvia.hofer@usz.ch